Singapore-based biotech company Nuevocor has raised $45 million in a Series B funding round to advance the treatment for patients with cardiomyopathies, a form of heart disease that could lead to heart failure, according to a statement on Tuesday.
The round was co-led by Eurazeo’s healthcare venture capital arm, Kurma Partners, and Rome-headquartered Angelini Ventures, which are getting board seats for their executives Amanda Gett-Chaperot and Elia Stupka, respectively. Kurma is investing from its fourth biotech fund that netted 140 million euros in its first close in October 2024.
Also making a significant participation are existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund, alongside Highlight Capital and SEEDS Capital, per the statement.
The fresh funds will be used for the first phase of clinical trials of NVC-001, a gene therapy treatment for LMNA-related dilated cardiomyopathy, a genetic heart condition caused by mutations in the LMNA gene, which provides instructions for making proteins that help maintain the structure of a cell’s nucleus.
The condition could lead to the weakening and enlargement of the heart muscle, ultimately resulting in a rapid progression toward end-stage heart failure. It is estimated to affect more than 100,000 patients in the US and Europe, the statement said.
